Scholarlink

<p>Evaluating trends in Hepatitis C virus (HCV) prevalence is critical for tracking the progress in HCV elimination efforts. We evaluated the changes in the prevalence of HCV infection (HCV antibody) among people who inject drugs (PWID) participating in the National HIV Behavioral Surveillance in Los Angeles County (LAC). <b>S</b>teady decreases in HCV antibody seroprevalence over time was observed among PWID from 81.2% in 2012 to 64.9% in 2015, 59.1% in 2018, 50.1% in 2022, and 34.2% in 2024. Chronic HCV infection (positive on both antibody and RNA tests) also declined from 37.1% in 2018 to 30.6% in 2022 and 18.2% in 2024. This downward pattern is further supported by multivariable analyses which showed a consistent reduction in HCV prevalence over time (aPR = 0.91, 95% CI 0.89–0.92). The largest decreases occurred among participants aged ≥ 30 years and among female PWID, with both decreasing 9.1% annually. HCV antibody positivity remained significantly higher among males, those with lower education, daily injectors, participants with incarceration history, and those engaging in receptive syringe sharing. Decreases in HCV antibody and RNA prevalence, alongside improved sterile injection practices, greater awareness of HCV status, and increases in treatment uptake, may reflect the impact of harm reduction efforts at reducing transmission among PWID in LAC. To achieve and sustain equitable progress, it remains essential to continue expanding HCV testing and treatment, particularly for communities that have not yet fully benefited from these interventions.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Trends in HCV Prevalence and Risk Factors Among People who Inject Drugs in Los Angeles County, 2012–2024

  • 期刊论文

  • 发表日期：

    2026年2月26日

查看全文
  • Yingbo Ma,
  • Ekow Kwa Sey,
  • Hugo Santacruz,
  • Jennifer Kwon,
  • Pierre Chambers,
  • Siri Chirumamilla

摘要

Evaluating trends in Hepatitis C virus (HCV) prevalence is critical for tracking the progress in HCV elimination efforts. We evaluated the changes in the prevalence of HCV infection (HCV antibody) among people who inject drugs (PWID) participating in the National HIV Behavioral Surveillance in Los Angeles County (LAC). Steady decreases in HCV antibody seroprevalence over time was observed among PWID from 81.2% in 2012 to 64.9% in 2015, 59.1% in 2018, 50.1% in 2022, and 34.2% in 2024. Chronic HCV infection (positive on both antibody and RNA tests) also declined from 37.1% in 2018 to 30.6% in 2022 and 18.2% in 2024. This downward pattern is further supported by multivariable analyses which showed a consistent reduction in HCV prevalence over time (aPR = 0.91, 95% CI 0.89–0.92). The largest decreases occurred among participants aged ≥ 30 years and among female PWID, with both decreasing 9.1% annually. HCV antibody positivity remained significantly higher among males, those with lower education, daily injectors, participants with incarceration history, and those engaging in receptive syringe sharing. Decreases in HCV antibody and RNA prevalence, alongside improved sterile injection practices, greater awareness of HCV status, and increases in treatment uptake, may reflect the impact of harm reduction efforts at reducing transmission among PWID in LAC. To achieve and sustain equitable progress, it remains essential to continue expanding HCV testing and treatment, particularly for communities that have not yet fully benefited from these interventions.